How long before elective knee surgery should tirzepatide (Mounjaro) be stopped?

Perioperative Management of Tirzepatide (Mounjaro) Before Knee Surgery

There is insufficient high-quality evidence to provide definitive guidance on stopping tirzepatide before elective knee surgery, but based on current guidelines addressing GLP-1 receptor agonists and the pharmacokinetic profile of tirzepatide, a cautious approach of withholding the medication for at least 1 week (one dosing interval) before surgery is reasonable, with consideration for longer cessation periods in high-risk patients.

Current Evidence Landscape

The most recent American Diabetes Association guidelines explicitly acknowledge the knowledge gap: "There are little data on the safe use and/or influence of GLP-1 receptor agonists on glycemia and delayed gastric emptying in the perioperative period" 1. This statement from the 2024 Standards of Care represents the highest-quality guideline evidence available, and it notably does not provide specific cessation recommendations for GLP-1 receptor agonists like tirzepatide 1.

Key Pharmacologic Considerations

Tirzepatide has distinct pharmacokinetic properties that inform perioperative timing 2:

• Half-life: Approximately 5 days 2
• Time to steady state: 4 weeks of once-weekly administration 2
• Gastric emptying effects: Delay is largest after the first dose and diminishes over time 2
• Weekly dosing schedule: Administered once every 7 days 2

Primary Perioperative Concern: Aspiration Risk

The central safety issue with GLP-1 receptor agonists perioperatively is delayed gastric emptying leading to increased pulmonary aspiration risk 1. A 2025 multidisciplinary consensus from multiple UK anesthesia and diabetes societies addresses this concern, though it acknowledges conflicting data on the magnitude of risk 1. One study reported an odds ratio of 10.23 (95% CI: 2.94-35.82) for pulmonary aspiration in elective surgery with GLP-1 RA use 1.

However, there is uncertainty about aspiration risk in patients on long-term GLP-1 RA therapy due to potential tachyphylaxis effects on gastric emptying 1.

Practical Cessation Recommendations

For Tirzepatide Specifically:

Given tirzepatide's 5-day half-life and weekly dosing, consider the following approach:

• Minimum cessation period: Hold for at least 1 week (one missed dose) before elective knee surgery 2
• Preferred cessation period for higher-risk patients: Hold for 3 half-lives (approximately 15 days or 2 missed doses) to allow more complete drug clearance 1
• For patients taking tirzepatide for weight management (not diabetes): The medication should be withheld for at least three half-lives (approximately 15 days) 1

For Patients With Diabetes on Tirzepatide:

There is legitimate concern that prolonged cessation will worsen perioperative glycemic control 1. The ADA guidelines emphasize maintaining perioperative blood glucose between 100-180 mg/dL 1.

For these patients:

• Coordinate with endocrinology to optimize alternative glycemic management during the cessation period 1
• Monitor blood glucose at least every 2-4 hours while NPO and dose with short- or rapid-acting insulin as needed 1
• Target A1C <8% for elective surgeries whenever possible 1

Other Diabetes Medications for Comparison

The ADA provides clear guidance for other agents 1:

• Metformin: Hold on the day of surgery 1
• SGLT2 inhibitors: Discontinue 3-4 days before surgery 1
• Other oral agents: Hold the morning of surgery 1

Critical Caveats

1. No FDA-specific perioperative guidance: The Mounjaro prescribing information does not address perioperative cessation 2

2. Individual risk stratification needed: Consider patient-specific factors including:

   • Indication for tirzepatide (diabetes vs. weight management)
   • Baseline glycemic control
   • Type of anesthesia planned (general vs. regional)
   • Aspiration risk factors
   • Duration of therapy (acute vs. chronic use may have different gastric emptying effects) 1

3. Gastric emptying effects diminish over time: The delay in gastric emptying is most pronounced after the first dose and decreases with continued therapy 2, suggesting chronic users may have lower aspiration risk than the early data suggest 1

4. Resumption timing: After surgery, tirzepatide can be resumed once the patient tolerates oral intake and gastrointestinal function has normalized, typically following the regular weekly dosing schedule 2

Bottom Line Algorithm

For elective knee surgery in patients on tirzepatide:

1. Minimum approach: Hold for 1 week (one missed dose) before surgery
2. Conservative approach (preferred for general anesthesia or high aspiration risk): Hold for 2-3 weeks (2-3 missed doses, representing ~3 half-lives)
3. Coordinate diabetes management: Arrange alternative glycemic control with endocrinology if patient has diabetes
4. Maintain perioperative glucose 100-180 mg/dL with insulin as needed 1
5. Resume postoperatively: Once tolerating oral intake and normal GI function returns

This approach balances the theoretical aspiration risk against the need for continued metabolic management, acknowledging the significant evidence gaps in this area 1.